Board of Directors and CEO
Organization
Resource and skill requirements vary during project development and are purchased as needed. This organizational model is totally focused on value-generating project
Resource and skill requirements vary during project development and are purchased as needed. This organizational model is totally focused on value-generating project
Karin has extensive experience in corporate governance, corporate strategy, and financial management. Within healthcare, she is the co-founder and has served as the Chairman of the Board for 10 years of EQL Pharma AB and been holding the position as CEO at Respiratorius AB. She has further significant corporate experience through her decade long experience as the CEO of Bomill AB. Her financial management roles have included corporate finance positions at Sedermera Corporate Finance Advisory AB and CFO of Nordic Drugs AB. She has also been on the BoD of Danske Bank AB.
Respiratorius strongly believes that Karin’s expertise in financial management, corporate governance and corporate strategy will be complementary to the BoD.
Additional Current Board Positions: Chairman of Duearity and Director at Diagonal Bio
Johan has an extensive experience in senior positions in medical device and pharmaceutical companies with a focus on research, business development and commercialization of research findings.
Kristina is associate professor at the Faculty of Medicine, Lund University and senior consultant of lymphoma oncology at Skåne University Hospital.
Mia Lundblad, holds a Master of Pharmacy degree from Uppsala University and a PhD in Clinical Pharmacology from Karolinska Institutet. Mia Lundblad has extensive experience in pharmaceutical research and development, project management, and business development from leading positions at Novo Nordisk, Ferring Pharmaceuticals, and Respiratorius. Currently, Mia Lundblad is the Clinical Pharmacology Scientific Director at Novo Nordisk and has previously served as CEO at Arcede Pharma.
Respiratorius AB (publ) develops candidate drugs with the goal of launching drugs to treat aggressive lymphoma (cancer).
Respiratorius AB
Medicon Village
Scheeletorget 1, 223 81 Lund, Sweden
info@respiratorius.com
+46 70 922 41 40